|Articles|June 26, 2011

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!

Latest CME

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Trending on Medical Economics

DOJ sues Louisiana hospital operator over unnecessary care, referral practices; heart disease, stroke drive more than one-quarter of U.S. deaths; red light therapy vs. CTE – Morning Medical Update

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Newsletter

Latest CME

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Trending on Medical Economics

DOJ sues Louisiana hospital operator over unnecessary care, referral practices; heart disease, stroke drive more than one-quarter of U.S. deaths; red light therapy vs. CTE – Morning Medical Update

Epic tells Texas AG: Our EHR systems are helping physicians treat patients across the country

PBM profits obscured by accounting and mergers, USC report finds

Agilent launches high-throughput digital pathology slide scanner in Europe

The risks and challenges physicians will face in 2026